MedTrace Logo

Adoptive Cell Therapy Across Cancer Diagnoses

NCT03296137 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

This study will perform tumor-infiltrating lymphocyte (TIL)-based adoptive T-cell therapy in combination with checkpoint inhibition on cancer patients across all cancer diagnoses.

Conditions

Interventions

BIOLOGICAL

Autologous tumor-infiltrating lymphocytes

Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.

DRUG

Ipilimumab

One treatment with ipilimumab (3 mg/kg) prior to tumor resection.

DRUG

Nivolumab

4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.

DRUG

proleukin

2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks

DRUG

Cyclophosphamide

2 doses (60 mg/kg) prior to TIL infusion

DRUG

Fludara

5 doses (25 mg/m2) prior to TIL infusion

Sponsors & Collaborators

  • Inge Marie Svane

    lead OTHER

Principal Investigators

  • Anders H Kverneland, MD · Center for Cancer Immune Therapy, Herlev Hospital

  • Inge Marie Svane, MD, Prof. · Center for Cancer Immune Therapy, Herlev Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-13
Primary Completion
2020-03-13
Completion
2020-07-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296137 on ClinicalTrials.gov